Functional Imaging of SDHx-related Head and Neck Paragangliomas: Comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine Scintigraphy, and 111In-pentetreotide Scintigraphy

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2011 Jul 15

PMID 21752889

Citations 49

Authors

Kathryn S King

Clara C Chen

Dimitrios K Alexopoulos

Millie A Whatley

James C Reynolds

Nicholas Patronas

Alexander Ling

Karen T Adams

Paraskevi Xekouki

Howard Lando

Constantine A Stratakis

Karel Pacak

Affiliations

Soon will be listed here.

Abstract

Rationale: Accurate diagnosis of head and neck paragangliomas is often complicated by biochemical silence and lack of catecholamine-associated symptoms, making accurate anatomical and functional imaging techniques essential to the diagnostic process.

Methods: Ten patients (seven SDHD, three SDHB), with a total of 26 head and neck paragangliomas, were evaluated with anatomical and functional imaging. This study compares five different functional imaging techniques [(18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) positron emission tomography (PET), (18)F-fluorodopamine ((18)F-FDA) PET/computed tomography (CT), (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/CT, (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy, and (111)In-pentetreotide scintigraphy] in the localization of head and neck paragangliomas.

Results: Prospectively (18)F-FDOPA PET localized 26 of 26 lesions in the 10 patients, CT/magnetic resonance imaging localized 21 of 26 lesions, (18)F-FDG PET/CT localized 20 of 26 lesions, (111)In-pentetreotide scintigraphy localized 16 of 25 lesions, (18)F-FDA PET/CT localized 12 of 26 lesions, and (123)I-MIBG scintigraphy localized eight of 26 lesions. Differences in imaging efficacy related to genetic phenotype, even in the present small sample size, included the negativity of (18)F-FDA PET/CT and (123)I-MIBG scintigraphy in patients with SDHB mutations and the accuracy of (18)F-FDG PET/CT in all patients with SDHD mutations, as compared with the accuracy of (18)F-FDG PET/CT in only one patient with an SDHB mutation.

Conclusion: Overall, (18)F-FDOPA PET proved to be the most efficacious functional imaging modality in the localization of SDHx-related head and neck paragangliomas and may be a potential first-line functional imaging agent for the localization of these tumors.

Citing Articles

Paragangliomas of the Head and Neck: A Review of the Latest Diagnostic and Treatment Methods.

Palade D, Hainarosie R, Zamfir A, Vrinceanu D, Pertea M, Tusaliu M Medicina (Kaunas). 2024; 60(6).

PMID: 38929531 PMC: 11205799. DOI: 10.3390/medicina60060914.

A Case of Pheochromocytoma With Coagulation Necrosis Due to Hypertensive Crisis Aggravated by Contrast-Enhanced CT Scan and Negative 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy.

Kobayashi A, Ishinoda Y, Uto A, Ogata S, Oshima N Cureus. 2024; 16(3):e56878.

PMID: 38659567 PMC: 11040423. DOI: 10.7759/cureus.56878.

The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options and Future Cluster Oriented Perspectives.

Bracigliano A, Marretta A, Guerrera L, Simioli R, Clemente O, Granata V Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543140 PMC: 10975789. DOI: 10.3390/ph17030354.

Imaging of Pheochromocytomas and Paragangliomas.

Timmers H, Taieb D, Pacak K, Lenders J Endocr Rev. 2024; 45(3):414-434.

PMID: 38206185 PMC: 11074798. DOI: 10.1210/endrev/bnae001.

Image-Guided Precision Medicine in the Diagnosis and Treatment of Pheochromocytomas and Paragangliomas.

Gabiache G, Zadro C, Rozenblum L, Vezzosi D, Mouly C, Thoulouzan M Cancers (Basel). 2023; 15(18).

PMID: 37760633 PMC: 10526298. DOI: 10.3390/cancers15184666.

References

Taieb D, Tessonnier L, Sebag F, Niccoli-Sire P, Morange I, Colavolpe C . The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol (Oxf). 2008; 69(4):580-6. DOI: 10.1111/j.1365-2265.2008.03257.x. View

Krenning E, Bakker W, Kooij P, Breeman W, Oei H, de Jong M . Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992; 33(5):652-8. View

Taieb D, Sebag F, Barlier A, Tessonnier L, Palazzo F, Morange I . 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature?. J Nucl Med. 2009; 50(5):711-7. DOI: 10.2967/jnumed.108.060731. View

Kayani I, Groves A . 18F-fluorodeoxyglucose PET/CT in cancer imaging. Clin Med (Lond). 2006; 6(3):240-4. PMC: 4953660. DOI: 10.7861/clinmedicine.6-3-240. View

Ilias I, Chen C, Carrasquillo J, Whatley M, Ling A, Lazurova I . Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008; 49(10):1613-9. PMC: 2614907. DOI: 10.2967/jnumed.108.052373. View

Brink I, Schaefer O, Walz M, Neumann H . Fluorine-18 DOPA PET imaging of paraganglioma syndrome. Clin Nucl Med. 2005; 31(1):39-41. DOI: 10.1097/01.rlu.0000191577.39458.a0. View

Timmers H, Kozupa A, Chen C, Carrasquillo J, Ling A, Eisenhofer G . Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007; 25(16):2262-9. DOI: 10.1200/JCO.2006.09.6297. View

Pacak K, Eisenhofer G, Goldstein D . Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev. 2004; 25(4):568-80. DOI: 10.1210/er.2003-0032. View

Neumann H, Pawlu C, Peczkowska M, Bausch B, McWhinney S, Muresan M . Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004; 292(8):943-51. DOI: 10.1001/jama.292.8.943. View

10.

Havekes B, King K, Lai E, Romijn J, Corssmit E, Pacak K . New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf). 2009; 72(2):137-45. PMC: 2966973. DOI: 10.1111/j.1365-2265.2009.03648.x. View

11.

Linnoila R, KEISER H, Steinberg S, Lack E . Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol. 1990; 21(11):1168-80. DOI: 10.1016/0046-8177(90)90155-x. View

12.

Chrisoulidou A, Kaltsas G, Ilias I, Grossman A . The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007; 14(3):569-85. DOI: 10.1677/ERC-07-0074. View

13.

Pauwels E, Sturm E, Bombardieri E, Cleton F, Stokkel M . Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol. 2000; 126(10):549-59. DOI: 10.1007/pl00008465. View

14.

Meyer-Rochow G, Schembri G, Benn D, Sywak M, Delbridge L, Robinson B . The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol. 2009; 17(2):392-400. DOI: 10.1245/s10434-009-0850-5. View

15.

Kwekkeboom D, van Urk H, Pauw B, Lamberts S, Kooij P, Hoogma R . Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med. 1993; 34(6):873-8. View

16.

Hoegerle S, Ghanem N, Altehoefer C, Schipper J, Brink I, Moser E . 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging. 2003; 30(5):689-94. DOI: 10.1007/s00259-003-1115-3. View

17.

Muros M, Llamas-Elvira J, Rodriguez A, Ramirez A, Gomez M, Arraez M . 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma. Nucl Med Commun. 1998; 19(8):735-42. DOI: 10.1097/00006231-199808000-00003. View

18.

Erickson D, Kudva Y, Ebersold M, Thompson G, Grant C, Van Heerden J . Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001; 86(11):5210-6. DOI: 10.1210/jcem.86.11.8034. View

19.

Pearse A . The APUD concept and hormone production. Clin Endocrinol Metab. 1980; 9(2):211-22. DOI: 10.1016/s0300-595x(80)80030-2. View

20.

Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I . Pheochromocytomas: detection with 18F DOPA whole body PET--initial results. Radiology. 2002; 222(2):507-12. DOI: 10.1148/radiol.2222010622. View